Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8IQ0D
|
|||
| Drug Name |
ME-401
|
|||
| Synonyms |
Zandelisib; UNII-8Z28M5SX0X; 8Z28M5SX0X; 4-yl)-1,3,5-triazin-2-amine; 1401436-95-0; [2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl}-6-(morpholin-; 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-N-{2-methyl-1-; Zandelisib [INN]; Zandelisib [USAN]; SCHEMBL12936730; GTPL10627; ACC-524; PWT-143; ME401; PW-143; WHO 11202; ZINC148868634; Example 51 [WO2012135160A1]; HY-109198; CS-0119144; A35 [WO2012135160A1]; 1,3,5-Triazin-2-amine, 4-(2-(difluoromethyl)-1H-benzimidazol-1-yl)-N-(1,1-dimethyl-2-(2-(1-methyl-4-piperidinyl)phenyl)ethyl)-6-(4-morpholinyl)-; 4-(2-(Difluoromethyl)benzimidazol-1-yl)-N-(1,1-dimethyl-2-(2-(1-methyl-4-piperidyl)phenyl)ethyl)-6-morpholino-1,3,5-triazin-2-amine; 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 2 | [1] | |
| Company |
MEI Pharma; Kyowa Kirin
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H38F2N8O
|
|||
| Canonical SMILES |
CC(C)(CC1=CC=CC=C1C2CCN(CC2)C)NC3=NC(=NC(=N3)N4CCOCC4)N5C6=CC=CC=C6N=C5C(F)F
|
|||
| InChI |
1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38)
|
|||
| InChIKey |
WPFUFWIHMYZXSF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1401436-95-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03768505) Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.